Open Access
Where are we going with CML research?
Leukemia Supplements · 2012
DOI: 10.1038/leusup.2012.26 ↗Kurz gefasst
Fachartikel in der Zeitschrift Leukemia Supplements, 2012. Verfasst von D Perrotti. Beteiligte Einrichtung: Department of Microbiology, Immunology and Medical Genetics, Comprehensive Cancer Center, The Ohio State University , Columbus, OH, USA. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
BCR-ABL1FTY720Janus kinase 2chronic myelogenous leukemialeukemic hematopoietic stem cellsprotein phosphatase 2A
Autor:innen und Institutionen
- Department of Microbiology, Immunology and Medical Genetics, Comprehensive Cancer Center, The Ohio State University , Columbus, OH, USA.
Zitieren
APA
Perrotti, D. (2012). Where are we going with CML research?. Leukemia Supplements. https://doi.org/10.1038/leusup.2012.26
Vancouver
Perrotti D. Where are we going with CML research?. Leukemia Supplements. 2012. doi:10.1038/leusup.2012.26
BibTeX
@article{Perrotti2012,
author = {Perrotti, D},
title = {Where are we going with CML research?},
journal = {Leukemia Supplements},
year = {2012},
doi = {10.1038/leusup.2012.26}
}
EUVIMED